EverGlade Taps DoD Vet to Guide Innovators Through Funding Maze

HOUSTON, TX – April 08, 2026 – Advisory firm EverGlade has announced a strategic hire poised to deepen its influence within the complex federal research and development landscape. Dr. Patrick Sims, a former leader within the Department of Defense's advanced research ecosystem, has joined the firm as a Managing Consultant, bringing over a decade of experience managing massive, high-stakes government programs.

The move signals a significant enhancement of EverGlade's capabilities, particularly in the lucrative and highly competitive sectors of biotechnology, national security, and life sciences. The firm specializes in guiding innovators through the labyrinthine process of securing non-dilutive federal funding—a critical lifeline for companies developing next-generation technologies.

A Strategic Play in a High-Stakes Field

EverGlade operates in a niche but crucial market, helping companies connect their innovations with government agencies like the Department of Defense (DoD), the Department of Health and Human Services (HHS), and the advanced research agencies that fall under them. In this environment, deep institutional knowledge is a paramount asset. Dr. Sims’ appointment is a clear move to acquire just that.

"Patrick brings a rare combination of firsthand experience inside the federal funding ecosystem and deep technical expertise," said Giacomo Apadula, CEO of EverGlade, in a statement. "His experience leading technical teams of scientists and engineers... strengthens our ability to guide innovators through complex programs and deepens the capabilities we bring to every client engagement."

This hire places EverGlade in a stronger competitive position against other consulting firms that vie to help clients secure a piece of the federal R&D budget, which is projected to top $200 billion for Fiscal Year 2025. By embedding a former high-level government program manager into its team, the firm gains an unparalleled perspective on how federal investment decisions are made, what makes a proposal successful, and how to manage the intricate post-award process.

The 'DARPA Insider' Advantage

Dr. Sims' resume reads like a map of the DoD's most ambitious scientific frontiers. Before joining EverGlade, he spent over ten years supporting the department, including extensive work with DARPA's Biological Technologies Office (BTO) and its Small Business Programs Office (SBPO). In his role at the Naval Information Warfare Center Pacific (NIWC Pacific), he provided technical and administrative oversight for more than 50 federal contracts and Other Transaction Agreements (OTAs) valued at over $500 million.

His portfolio included some of DARPA's most forward-looking initiatives, such as the Prometheus, THoR, P3, and NOW programs, which focus on everything from pandemic preparedness and rapid medical countermeasure development to advanced biomanufacturing. This experience provides an invaluable 'insider' perspective on what it takes to succeed in the high-risk, high-reward world of DARPA funding.

"Throughout my time supporting federal R&D programs, I've seen firsthand how challenging it can be for companies to navigate the funding landscape while advancing their science," Dr. Sims stated. He highlighted EverGlade's unique model of building strategic partnerships and supporting technical execution, noting, "I'm excited to join this talented team and to help innovators translate their concepts into successful programs."

Aligning with Federal R&D Priorities

The timing of Dr. Sims' arrival at EverGlade aligns perfectly with current federal spending priorities. The DoD and HHS are slated to receive the lion's share of the FY2025 R&D budget, with the DoD alone allocated nearly $93 billion. Much of this funding is directed toward the very areas of Dr. Sims' expertise.

In March 2023, the DoD released its Biomanufacturing Strategy, signaling a major push to develop a self-sustaining domestic ecosystem for producing materials and medicines vital to national security. Likewise, the department's Science & Technology budget prioritizes trusted AI and autonomy, integrated sensing, and quantum computing. Dr. Sims' background in facilitating research across AI/ML, chemical and biological sensing, and quantum computing makes him an ideal guide for companies looking to contribute to these national priorities.

His experience on source selection evaluation boards for both DARPA and IARPA (Intelligence Advanced Research Projects Activity) gives him a unique understanding of the criteria used to make federal investment decisions, an advantage that EverGlade will undoubtedly leverage for its clients aiming to secure funding in these cutting-edge fields.

Navigating the 'Revolving Door'

The transition of high-level government officials like Dr. Sims into the private consulting sector is a well-known phenomenon often dubbed the 'revolving door.' This practice is common in the federal contracting industry and carries both significant benefits and potential ethical scrutiny.

On one hand, the expertise brought by former officials can create immense efficiencies. They understand the bureaucracy, the unwritten rules, and the precise language required to align a private company's goals with a federal agency's mission. This knowledge transfer can accelerate innovation and help taxpayers' money get to the most promising projects faster.

On the other hand, the practice is monitored by government ethics watchdogs for potential conflicts of interest or unfair competitive advantages. Federal laws and regulations from the Office of Government Ethics (OGE) place strict 'cooling-off' periods and restrictions on former employees to prevent them from improperly leveraging their government contacts or inside information. The hiring of former officials is a standard, strategic practice in the industry, but one that requires careful navigation of these ethical and legal guardrails.

A Proven Track Record Amplified

EverGlade is not new to the winner's circle. The firm has a documented history of securing major funding for its clients. It helped biotech firm SonALAsense secure up to $46 million from the newly formed ARPA-H to develop a novel cancer treatment. It also assisted United Safety Technology in landing a $97 million DoD award to bolster domestic production of nitrile gloves and helped Detect, Inc. secure $22 million for a next-generation COVID-19 and flu test.

With Dr. Sims on board, EverGlade is positioned to amplify this success. His deep expertise in the national security and advanced defense research sectors opens up new avenues and adds another layer of credibility to the firm’s proposals. For innovators working on the next breakthrough in biotechnology, artificial intelligence, or quantum science, having a guide who has navigated the very system they seek to enter could mean the difference between a concept on a whiteboard and a fully funded program addressing the nation's most complex challenges.